ADIL · Adial Pharmaceuticals Inc
United States · RS rating 43 · As of 2026-10-14
| Price | 3.00 USD |
|---|---|
| 1-day change | -8.8% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 3 / 83 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 28 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -660.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +69.2% |
| Market cap (USD) | $2.2M |